Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. Chief Operating Officer Laurent R. Moll executed an open-market sale of common stock. On April 14, 2026, he sold 13,448 shares at a weighted average price of $20.0313 per share in multiple transactions.
After this sale, he directly holds 265,530 shares of Arteris common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 12, 2026, indicating the sales were pre-scheduled rather than opportunistic. Individual trade prices ranged from $19.90 to $20.22 per share.
Arteris, Inc. director Raman Chitkara sold shares in an open-market transaction. On this date, he sold 5,000 shares of common stock at a weighted average price of $20.0508 per share, with individual sale prices ranging from $20.00 to $20.13. After the sale, he directly holds 152,867 shares, indicating the transaction represents a small portion of his overall position.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan. He sold a total of 1,993 shares of common stock at a weighted average price around $19.90 per share and continues to hold 278,979 shares directly.
Laurent Moll reported securities transactions via a Form 144, listing Restricted Stock Units and recent sales executed under a 10b5-1 plan. The filing cites an RSU grant dated 03/15/2022 and three sales: 04/02/2026 (5,602 shares, $98,890.99), 04/06/2026 (1,552 shares, $28,292.96), and 04/10/2026 (990 shares, $19,701.00).
AIP notice of proposed sales of Common Stock under Rule 144 and a 10b5-1 plan. The filing lists two recent planned sales: 1,552 shares on 04/06/2026 (value $28,292.96) and 5,602 shares on 04/02/2026 (value $98,890.99).
The record also references Restricted Stock Units dated 03/15/2022 as the source of shares. The filing is a notice of intent to sell and does not itself report completed market transactions.
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of Common Stock at a weighted average price of $19.0398 per share. The shares were sold on April 8, 2026 by Bayview Legacy, LLC, an entity for which Janac serves as manager and has voting and dispositive power.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. After the transactions reported, indirect holdings through Bayview Legacy, LLC were 9,119,071 shares, direct holdings were 196,729 shares, and 56,252 shares were held indirectly via the Charles and Lydia Janac Trust, for which Janac serves as trustee.
Bayview Legacy, LLC, a ten percent owner of Arteris, Inc., reported an open-market sale of 70,000 shares of Arteris common stock. The sale occurred on April 8, 2026 at a weighted average price of $19.0398 per share, with individual trade prices ranging from $18.67 to $19.43.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025 by K. Charles Janac, the manager of Bayview Legacy, LLC. Following the sale, Bayview Legacy, LLC indirectly held 9,119,071 shares of Arteris common stock, over which Janac is deemed to have voting and dispositive power.
AIP filed a Form 144 notifying the proposed sale of 70,000 shares of Common Stock. The cover line lists an aggregate value of $1,268,400.00 and shows Nasdaq as the market with an as of date of 04/08/2026. The filing also lists prior private acquisitions of 50,000 and 20,000 shares (11/05/2013 and 02/05/2016 respectively) and discloses recent 10b5-1 sales by related holders, including sales of 11,800 shares on 04/06/2026 for K. Charles Janac and 32,988 shares on 03/26/2026 for Bayview Legacy, LLC.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel received 899 shares of common stock as a fully vested restricted stock award. The award represents retainer fees he chose to take in shares instead of cash.
The grant was based on the average Arteris trading price of $15.98 over the period from February 20, 2026 through April 2, 2026. Following this award, he holds 69,627 shares of Arteris common stock directly. Kunkel elected to defer the receipt of these shares.